Nyrada Inc Annual Report
Please follow the link below to see the Annual Report for FY23.
Please follow the link below to see the Annual Report for FY23.
Highlights: • Research and development costs of $6.4M (FY2022: $1.8M), approximately 68% of expenditure. • Accrued (estimated) R&D rebate of… Read more
Cholesterol-Lowering Program: • Significant work completed during the quarter progressing and understanding the mechanisms underlying Nyrada’s cholesterol-lowering program drug candidate… Read more
Nyrada Inc (ASX:NYR) (“Nyrada” or “Company”), a drug development company specialising in novel small molecule drugs to treat cardiovascular and… Read more
Nyrada Inc (ASX: NYR), a drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases,… Read more
New brain injury drug candidate NYR-BI03 to be advanced instead of NYR-BI02 due to demonstrated superior potency and safety profile,… Read more
• All required preclinical safety and toxicology studies have been completed, supporting advancement to a first-in-human clinical trial • Submission… Read more
Highlights: • Cholesterol-Lowering Program: – Preclinical dose formulation work finalised – Remaining safety and pharmacology studies to be completed end… Read more
• Preclinical dose formulation work has been completed • Toxicology studies have been completed, safety and pharmacology studies to be… Read more